A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Background: Major depressive disorder is a common condition that often includes cognitive dysfunction. A systematic literature review of studies and a network meta-analysis were carried out to assess the relative effect of antidepressants on cognitive dysfunction in major depressive disorder. Methods: MEDLINE, Embase, Cochrane, CDSR, and PsychINFO databases; clinical trial registries; and relevant conference abstracts were searched for randomized controlled trials assessing the effects of antidepressants/placebo on cognition. A network meta-analysis comparing antidepressants was conducted using a random effects model. Results: The database search retrieved 11337 citations, of which 72 randomized controlled trials from 103 publications met the inclusion criteria. The review identified 86 cognitive tests assessing the effect of antidepressants on cognitive functioning. However, the Digit Symbol Substitution Test, which targets multiple domains of cognition and is recognized as being sensitive to change, was the only test that was used across 12 of the included randomized controlled trials and that allowed the construction of a stable network suitable for the network meta-analysis. The interventions assessed included selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and other non-selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors. The network meta-analysis using the Digit Symbol Substitution Test showed that vortioxetine was the only antidepressant that improved cognitive dysfunction on the Digit Symbol Substitution Test vs placebo {standardized mean difference: 0.325 (95% CI = 0.120; 0.529, P=.009}. Compared with other antidepressants, vortioxetine was statistically more efficacious on the Digit Symbol Substitution Test vs escitalopram, nortriptyline, and the selective serotonin reuptake inhibitor and tricyclic antidepressant classes. Conclusions: This study highlighted the large variability in measures used to assess cognitive functioning. The findings on the Digit Symbol Substitution Test indicate differential effects of various antidepressants on improving cognitive function in patients with major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among 72 randomized controlled trials, vortioxetine showed a significant cognitive benefit over placebo (standardized mean difference = 0.325, p = 0.009) and was superior to escitalopram, nortriptyline, SSRIs, and tricyclic antidepressants.”
From Efficacy of Vortioxetine Versus Escitalopram on the Cognitive Profile of Patients With Depressive Disorder: A Comparative Study (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, a network meta-analysis shows that Vortioxetine provides statistically significant improvements in cognitive function compared with other antidepressants, possibly due to its unique pharmacological profile.20”
From A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A study of a larger scale comparing the effects of antidepressants on cognitive function measured by DSST demonstrated that Vortioxetine was more efficacious than Escitalopram and other antidepressants.20”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
Cognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161 · cited 1×
“7 standardized mean differences below what would be normal, depending on disease state and cognitive domain (Rund et al., 2006; Lee et al., 2012; Rock et al., 2014).”
BackgroundDIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, FIFTH EDITION
Abbas, A., & Aminoroaia, M. (2013) · Cited by 1,479
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · cited 5×
“In addition, cognitive improvements with vortioxetine may be due to direct and/or indirect effects via serotonergic, noradrenergic, cholinergic, dopaminergic, and histaminergic systems (Elmaadawi et al., 2015; Sanchez et al., 2015).”
BackgroundInfluentialConradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515
Research works printed but not linked: 5
- European Medicines Agency, 2016, Brintellix summary of product characteristics
- Food and Drug Administration, 2016, Psychopharmacologic Drugs Advisory Committee: (PDAC) Meeting
- Haddjeri, 2012, Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition, In: European Neuropsychopharmacology, 22, S303
- NICE, 2013, Specification for manufacturer/sponsor submission of evidence
- World Health Organization, 2016, Fact sheet N°369
Cited by
Jaeger, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000941 · Cited by 836
Marx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
HIV, Depression, and Cognitive Impairment in the Era of Effective Antiretroviral Therapy
Rubin, L. H., & Maki, P. M. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00421-0 · Cited by 178
O’Connor, E., Perdue, L. A., Coppola, E. L., Henninger, M. L., Thomas, R. G., & Gaynes, B. N. (2023) · JAMA · doi:10.1001/jama.2023.7787 · Cited by 126
Li, H., Sagar, A. P., & Kéri, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.021 · Cited by 102
Rhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 102
Cognitive dysfunctions in depression – significance, description and treatment prospects
Czerwińska, A., & Pawłowski, T. (2020) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/105415 · Cited by 85
Christensen, M. C., Wong, C. M. J., & Baune, B. T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00280 · Cited by 82
Self-citationMorrens, M., Overloop, C., Coppens, V., Loots, E., Noortgate, M. V. D., Vandenameele, S., Leboyer, M., & Picker, L. D. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01582-y · Cited by 82
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
“In addition to its antidepressant effects, vortioxetine has demonstrated cognitive-enhancing properties in humans in seven short-term RCTs (6–12 weeks) (26–35), three meta-analyses (28, 30, 38), and one open-label trial (62), wherein cognitive function was the primary outcome of interest.”
BackgroundBaune, B. T., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.056 · Cited by 73
Self-citationDe Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Malpetti, M., Jones, P. S., Tsvetanov, K. A., Rittman, T., van Swieten, J. C., Borroni, B., Sanchez‐Valle, R., Moreno, F., Laforce, R., Graff, C., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12252 · Cited by 59
Liu, Y., Chen, Y., Liang, X., Li, D., Zheng, Y., Zhang, H., Cui, Y., Chen, J., Liu, J., & Qiu, S. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00272 · Cited by 65
Mugge, L., Mansour, T. R., Crippen, M., Alam, Y., & Schroeder, J. L. (2018) · Neurosurgical Review · doi:10.1007/s10143-018-1017-2 · Cited by 65
Wang, G., Si, T., Li, L., Fang, Y., Wang, C., Wang, L., Tan, K. H. X., Ettrup, A., Eriksen, H. F., Luo, S., et al. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s195505 · Cited by 55
Comparative analysis of default mode networks in major psychiatric disorders using resting-state EEG
Choi, K., Kim, J.-Y., Kim, Y.-W., Han, J., Im, C., & Lee, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00975-3 · Cited by 48
Inoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
Ahern, E., White, J., & Slattery, E. J. (2024) · Neuropsychology Review · doi:10.1007/s11065-023-09629-9 · Cited by 50
Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz062 · Cited by 38
Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain
Zuena, A. R., Maftei, D., Alemà, G., Moro, F. D., Lattanzi, R., Casolini, P., & Nicoletti, F. (2018) · Molecular Pain · doi:10.1177/1744806918808987 · Cited by 40
Levada, O. A., & Troyan, A. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.040 · Cited by 37
Moreno, M., Goerigk, S. A., Bertola, L., Suemoto, C. K., Razza, L. B., Moffa, A. H., Veronezi, B. P., Tort, L. C., Nogueira, B. S., Gattaz, W. F., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.12.009 · Cited by 36
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update
Adamo, D., Calabria, E., Coppola, N., Pecoraro, G., & Mignogna, M. D. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211034320 · Cited by 38
Biederman, J., Lindstén, A., Sluth, L. B., Petersen, M. L., Ettrup, A., Eriksen, H. F., & Fava, M. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119832538 · Cited by 33
Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation
Fukuyama, K., Motomura, E., & Okada, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032070 · Cited by 36
Cognitive functioning and lifetime major depressive disorder in UK Biobank
de Nooij, L., Harris, M. A., Adams, M. J., Clarke, T., Shen, X., Cox, S. R., McIntosh, A. M., & Whalley, H. C. (2020) · European Psychiatry · doi:10.1192/j.eurpsy.2020.24 · Cited by 36
Liu, L., Lv, X., Zhou, S., Liu, Q., Wang, J., Tian, H., Zhang, K., Wei, J., Wang, C., Chen, Q., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.020 · Cited by 32
Predictors of cognitive impairment in treatment-resistant depression
Gregory, E., Torres, I. J., Ge, R., Blumberger, D. M., Downar, J. H., Daskalakis, Z. J., Lam, R. W. M., & Vila‐Rodriguez, F. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.101 · Cited by 31
Xu, Y., Chen, A., Chen, R., & Zheng, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.165 · Cited by 31
Association between Serum Lipid Parameters and Cognitive Performance in Older Adults
Lee, J., Lee, S., Min, J., & Min, K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10225405 · Cited by 31
Vortioxetine – pharmacological properties and use in mood disorders. The current state of knowledge
Krupa, A. J., Wojtasik-Bakalarz, K., & Siwek, M. (2022) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/151570 · Cited by 31
Vortioxetine improves cognition in mild cognitive impairment
Tan, S. N., & Tan, C. S. C. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000376 · Cited by 31
Nicola, M. D., Pepe, M., Montanari, S., Spera, M. C., Panaccione, I., Simonetti, A., & Sani, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.006 · Cited by 27
Haro, J. M., Hammer-Helmich, L., Saragoussi, D., Ettrup, A., & Larsen, K. G. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s206825 · Cited by 30
Self-citationKatayama, N., Nakagawa, A., Umeda, S., Terasawa, Y., Abe, T., Kurata, C., Sasaki, Y., Mitsuda, D., Kikuchi, T., Tabuchi, H., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.11.034 · Cited by 25
An update on potential pharmacotherapies for cognitive impairment in bipolar disorder
Johnson, D. E., McIntyre, R. S., Mansur, R. B., & Rosenblat, J. D. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2194488 · Cited by 25
Badulescu, S., Gill, H., Shah, H., Brudner, R. M., Phan, L., Vincenzo, J. D. D., Tabassum, A., Armanyous, M., Llach, C.-D., Rosenblat, J. D., et al. (2025) · Med · doi:10.1016/j.medj.2025.100916 · Cited by 28
Relationship between peripheral neuropathy and cognitive performance in the elderly population
Lin, Y., Kao, T., & Chen, W. (2021) · Medicine · doi:10.1097/md.0000000000026071 · Cited by 24
Filippis, S. D., Martinotti, G., Nicoletti, F., Mastrostefano, A., Trovini, G., Pugliese, A., & Nicola, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240827165327 · Cited by 23
Zhou, J., Ma, L., Zhao, L., Sheng, J., Xu, Y., Chen, J., Yu, L., Sun, Q., Zhou, H., Zhu, S., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210141 · Cited by 22
Padovani, A., Antonini, A., Barone, P., Bellelli, G., Fagiolini, A. M., Ferini‐Strambi, L., Sorbi, S., & Stocchi, F. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06891-w · Cited by 23
Nicola, M. D., Pepe, M., Panaccione, I., Moccia, L., Dattoli, L., Molinaro, M., Sani, G., Janiri, L., & McIntyre, R. S. (2020) · CNS Spectrums · doi:10.1017/s109285292000173x · Cited by 22
Šagud, M., Perković, M. N., Dvojkovic, A., Jakšić, N., Vuksan‐Ćusa, B., Živković, M., Kušević, Z., Mihaljević-Peleš, A., & Pivac, N. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05790-2 · Cited by 22
Toffanin, T., Folesani, F., Ferrara, M., Murri, M. B., Zerbinati, L., Caruso, R., Nanni, M. G., Koch, G., Fadiga, L., Palagini, L., et al. (2022) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2022.10.001 · Cited by 22
Chokka, P. R., Tvistholm, A. H., Bougie, J. K., Clerzius, G., & Ettrup, A. (2020) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000001805 · Cited by 21
Wang, H., Tian, S., Yan, R., Tang, H., Shi, J., Zhu, R., Chen, Y., Han, Y., Chen, Z., Zhou, H., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.126 · Cited by 19
Wang, L., Huo, Y., Yao, L., Zhang, N., Ma, S., Nie, Z., Wang, W., Zhou, E., Xu, S., Weng, S., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1494032 · Cited by 18
Wang, G., Tan, K. H. X., Ren, H., & Hammer-Helmich, L. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s230403 · Cited by 18
Koshikawa, Y., Nishida, K., Yamane, T., Yoshimura, M., Onohara, A., Ueda, S., Ishii, R., Kinoshita, T., & Morishima, Y. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13364 · Cited by 19
Contemporary methods of improving cognitive dysfunction in clinical depression
Knight, M. J., Mills, N. T., & Baune, B. T. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1610395 · Cited by 18
Self-citationCao, B., Xu, L., Chen, Y., Wang, D., Lee, Y. L., Rosenblat, J. D., Gao, X., Zhan, S., Sun, F., & McIntyre, R. S. (2021) · CNS Spectrums · doi:10.1017/s1092852921000171 · Cited by 21
Zu, S., Wang, D., Fang, J., Xiao, L., Zhu, X., Wu, W., Wang, G., & Hu, Y. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s317770 · Cited by 19
Wang, P., Yan, F., Dong, J., Wang, S., Shi, Y., Zhu, M., Zuo, Y., Ma, H., Xue, R., Zhai, D., et al. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp05676c · Cited by 16
Gao, Y., Su, D., Xue, Z., Ji, L., & Wang, S. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00555-9 · Cited by 15
Erythropoietin and Non-Erythropoietic Derivatives in Cognition
Newton, S. S., & Sathyanesan, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728725 · Cited by 16
Interventions of cognitive impairment in older adults: A comprehensive review
Chib, S., Sharma, K., & Singh, R. (2025) · Aging and Health Research · doi:10.1016/j.ahr.2025.100223 · Cited by 16
Yang, X., Fang, S., Lyu, W., Hu, Y., Xu, H., Jiang, X., Zhao, Y., Zhang, Y., Li, J., & Kuang, W. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13709 · Cited by 15
Petelin, D. S., Bairamova, S., Sorokina, O. Y., Niinoja, I. N. V., Борисовна, Л. А., & Volel, B. A. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-5-96-102 · Cited by 13
Xia, Y., Hua, L., Dai, Z., Han, Y., Du, Y., Zhao, S., Zhou, H., Wang, X., Yan, R., Wang, X., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04844-3 · Cited by 13
Pepe, M., Bartolucci, G., Marcelli, I., Simonetti, A., Camardese, G., Nicola, M. D., & Sani, G. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000723 · Cited by 14
Cuomo, A., Aguglia, A., Berardis, D. D., Ventriglio, A., Gesi, C., & Fagiolini, A. M. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00505-1 · Cited by 13
Lu, P., Kezios, K., Yaffe, K. S., Kim, S., Zhang, A., Milazzo, F., & Hazzouri, A. Z. A. (2023) · Annals of Epidemiology · doi:10.1016/j.annepidem.2023.02.009 · Cited by 13
Depressive disorders and their pharmacotherapy in routine clinical practice
Mosolov, S. N., Parfenov, V. A., Амелин, А. В., Medvedev, V. E., Mendelevich, В. D., Михайлович, У. Г., Sivolap, Y. P., Bogolepova, A. N., Mkhitaryan, E. A., & Petelin, D. S. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-5-54-64 · Cited by 12
Baune, B. T., Boyce, P. M., Morris, G., Hamilton, A., Bassett, D. L., Hopwood, M., Mulder, R., Parker, G. B., Porter, R., Singh, A., et al. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418824026 · Cited by 12
Self-citationEffects of new hypnotic drugs on cognition: A systematic review and network meta-analysis
Zhou, M., Liu, R., Tang, J., & Shi, T. (2023) · Sleep Medicine X · doi:10.1016/j.sleepx.2023.100094 · Cited by 11
Risks Associated with Vortioxetine in the Established Therapeutic Indication
Verma, A., & Kumar, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200818195720 · Cited by 11
Depressive states in the structure of postcovid syndrome: features and therapy
Петрова, Н. Н., Kudryashov, A. V., Matvievskaya, O. V., Mukhin, A. A., Lavrova, V. A., Chumakov, E. M., Yaltseva, N. V., Kuzmina, S. V., Kostina, N. V., Akimova, E. V., et al. (2022) · V M BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY · doi:10.31363/2313-7053-2022-56-1-16-24 · Cited by 11
Adverse Events, Drug Interactions, and Treatment Adherence
Limandri, B. J. (2020) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20200117-02 · Cited by 11
Zhang, F., Liu, W., Zheng, Y., Liu, C., Hu, Y. G., Chen, H., Tang, X., Wei, Y., Zhang, T., Wang, J., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.011 · Cited by 10
Manna, C. K., Ranjan, R., Kumar, P., Ahmad, S., & Nath, S. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_160_23 · Cited by 9
Mattingly, G. W., Brunner, E., Chrones, L., Lawrence, D. F. E., Simonsen, K., & Ren, H. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.977560 · Cited by 10
Parsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function
Xu, C., Tao, Y., Lin, Y., Zhu, J., Li, Z., Li, J., Wang, M., Huang, T., & Shi, C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1537331 · Cited by 8
Sobreiro, M. D. F. M., Silveira, P. S. P., Cavenaghi, V. B., da Costa, L. P., de Souza, B. P. F., Takahashi, R. E. S., Starek, R. V. M., Siqueira, J. D. O., & Fráguas, R. (2025) · Pharmaceuticals · doi:10.3390/ph18020173 · Cited by 7
Wang, G., Zhao, K., Reynaud-Mougin, C., Loft, H., Ren, H., Eriksen, H. F., & Ettrup, A. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1723072 · Cited by 8
Wang, P., Jing, C., Pei, Y., Lu, M., Xu, X., Pei, Q., & Yan, F. (2021) · Technology and Health Care · doi:10.3233/thc-218024 · Cited by 7
Role of vortioxetine in the treatment of neuropathic pain
Montero, A. A., & de Vasconcelos, S. R. P. (2022) · Revista Española de Anestesiología y Reanimación (English Edition) · doi:10.1016/j.redare.2022.09.003 · Cited by 9
Memory and attention deficit in chronic migraine
Владимировна, Л. Н., Filatova, E. G., & Osipova, D. V. (2018) · Neuromuscular Diseases · doi:10.17650/2222-8721-2018-8-2-10-16 · Cited by 9
Singh, O. P., Avinash, P., Gautam, A., Prasad, A., & Jagawat, T. (2025) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_563_24 · Cited by 6
Robin, A., Sauvaget, A., Deschamps, T., Bulteau, S., & Thomas-Ollivier, V. (2019) · Psychiatry Investigation · doi:10.30773/pi.2019.0116 · Cited by 6
Lyu, Q.-Y., Cheung, D. S. K., Lai, H., Wang, X., Qiu, J., Huang, Y., & Zeng, Y. (2020) · Research in Nursing & Health · doi:10.1002/nur.22050 · Cited by 6
Ou, A., Wu, G. W. Y., Kassel, M. T., Mackin, R. S., Rampersaud, R., Reus, V. I., Mellon, S. H., & Wolkowitz, O. M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.115 · Cited by 6
Zhang, X., Niu, M.-M., Ma, P., Du, L. Z., & Wan, L. (2020) · Medicine · doi:10.1097/md.0000000000022344 · Cited by 6
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
Mills, N. T., Sampson, E., Fourrier, C., & Baune, B. T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa092 · Cited by 6
Self-citationHuang, X., Diao, Z., Shen, D., Li, J., Wang, J., Wang, K., & Qiu, S. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111417 · Cited by 5
Experience with vortioxetine in the treatment of post-stroke depression
Strelnikova, I. A., Светкина, А. А., Minina, Y. D., & Androfagina, O. V. (2020) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2020-1-45-49 · Cited by 5
McIntyre, R. S. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2522885 · Cited by 4
Brain Jogging: Cognitive Abilities of Beginner Tennis Players
Mulya, G., Lengkana, A. S., Agustryani, R., Dinangsit, D., Susilawati, D., Nurodin, D., & Rosalina, M. (2023) · International journal of human movement and sports sciences · doi:10.13189/saj.2023.110617 · Cited by 4
da Silva, C. P., Oliveira, D. D., Benincasa, B. I., Barbar, B., Perri, R. G. B., Fachin, A. L., Falconi‐Sobrinho, L. L., & Beleboni, R. O. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000781 · Cited by 4
Cognitive Dysfunction in the Workplace: Focus on Depression
Lam, R. W. M., & Persad, C. C. (2019) · Integrating psychiatry and primary care · doi:10.1007/978-3-030-04266-0_7 · Cited by 4
Papel de vortioxetina en el tratamiento del dolor neuropático
Montero, A. A., & de Vasconcelos, S. R. P. (2021) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2021.04.001 · Cited by 4
An improved kernel correlation filter for complex scenes target tracking
Huo, W., Yan, Y., Zhou, M., & Li, T. (2022) · Multimedia Tools and Applications · doi:10.1007/s11042-022-12669-7 · Cited by 4
Ye, X., Xu, P., Jiao, J., Zhao, H., Jin, K., Zhang, S., Pan, F., Chen, J., Jiang, H., Hu, J., et al. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s491768 · Cited by 3
Li, L., Li, C., Li, Z., & Zhu, J. (2025) · Medicine · doi:10.1097/md.0000000000045602 · Cited by 4
Chen, S., Huang, R., Zhang, M., Huang, X., Ling, S., Liu, S., & Yang, N. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1282496 · Cited by 3
Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder
Vicent-Gil, M., Trujols, J., Sagués, T., Serra-Blasco, M., Navarra‐Ventura, G., Mantellini, C. L., Crivillés, S., Portella, M. J., & Cardoner, N. (2025) · Annals of General Psychiatry · doi:10.1186/s12991-025-00552-2 · Cited by 3
Chronic pain, depression and cognitive impairment: a close relationship
Владимировна, Л. Н., Filatova, E. G., & Osipova, D. V. (2018) · Neuromuscular Diseases · doi:10.17650/2222-8721-2018-8-3-34-42 · Cited by 3
Atsou, K., Ereshefsky, L., Brignone, M., Danchenko, N., Diamand, F., Mucha, L., Touya, M., Becker, R., & François, C. (2021) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1855979 · Cited by 4
Self-citationAlmaguer‐Melian, W., Mercerón‐Martínez, D., Alberti‐Amador, E., Alacán‐Ricardo, L., de Bardet, J. C., Orama‐Rojo, N., Pina, A. B., Herrera-Estrada, I., & Bergado, J. A. (2023) · Synapse · doi:10.1002/syn.22282 · Cited by 3
Zajecka, J., Laufer, O., Peremen, Z., Sholtes, D., Mackey, I., Baumeister, C., White, A., Geva, A. B., & Issachar, G. (2024) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2024.100732 · Cited by 3
Metadata
- Authors
- Baune, B. T., Brignone, M., & Larsen, K. G.
- Affiliations
- The University of Adelaide (AU)
- Lundbeck SAS, Issy-les-Moulineaux, France
- Lundbeck (Denmark) (DK)
- Corresponding author
- Brignone, Mélanie
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-19
- Volume
- 21
- Issue
- 2
- Pages
- 97-107
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5793828
- OpenAlex
- W2765333294
- Cited by
- 140
- References
- 42
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 16 · 2023: 20 · 2022: 11 · 2021: 22 · 2020: 18 · 2019: 16 · 2018: 6 · 2017: 1
- FWCI
- 7.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
- Funders
- H. Lundbeck A/S and Takeda Pharmaceutical Company, Ltd
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, cognitive impairment, antidepressants, Digit Symbol Substitution Test, vortioxetine, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, escitalopram, nortriptyline
- MeSH terms
- Network Meta-Analysis, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Neuropsychological Tests, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.